1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
693A630ABE4AD14F085257D3B006B7C3C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-big-data-in-pharma-budgets-staffing-communicating-results-and-group-performance?opendocument
18
19opendocument
2054.226.58.177
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services ╗ Market Research, Analytics and ForecastingAnalytics

Big Data in Pharma: Budgets & Staffing, Communicating Results, and Group Performance

ID: 5325


Features:

23 Info Graphics

13 Data Graphics

150+ Metrics

10 Narratives


Pages/Slides: 45


Published: 2014


Delivery Format: Online PDF Document


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Big Data in Pharma: Budgets & Staffing, Communicating Results, and Group Performance"


STUDY OVERVIEW

The last decade has seen an explosion in the availability of data that can deliver valuable insights for the pharmaceutical sector– from Electronic Medical Records and clinical trial data to medical claims and patient behavior data. All these information types are part of the large and complex data sets that make up what’s called Big Data.

The inherent costs and challenges that come with harnessing large sets of information in varied formats have caused the pharmaceutical sector to embrace Big Data analytics slower than other industries. As organizations move to develop Big Data capabilities they are wrestling with questions such as what is the appropriate staffing and budget levels, what data capabilities do we need and should analytics be centralized or decentralized?

Best Practices, LLC undertook this study to probe these issues as well as current trends and best practices in utilizing Big Data in the pharmaceutical sector. The study offers key benchmarks around staffing and budget levels, the dissemination of data analysis, Big Data capabilities and analysis of centralized vs. decentralized structural approaches for analytics.


KEY TOPICS

  • Executive Summary
  • Big Data Team Overview and Key Study Insights
  • Quantitative Key Findings
  • Qualitative Key Findings
  • Defining Big Data
  • Budgets and Staff
  • Communicating Results
  • Performance

SAMPLE KEY METRICS
  • Approximate current budget range for Big Data spending categories
  • Approximate number of FTEs providing/managing Big Data initiatives, projects
  • Approximate number of Big Data FTEs by company size (revenue)
  • The most impacted target audiences for data analysis
  • Most common ways for disseminating real world data analysis
  • Indicate level of maturity within your organization for these data capabilities

SAMPLE KEY FINDING
  • Internal Groups Rated as Most Impactful Targets for Data Analysis: Internal Commercial, Medical and Development functions were rated by a majority of respondents as the most impactful targets for data analysis presentations. They were also the most frequent requestors of presentations.

METHODOLOGY

Best Practices, LLC engaged 22 leaders from 18 pharmaceutical companies through a benchmarking survey.áResearch analysts also conducted seven deep-dive executive interviews with selected benchmarká participants.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Merck; Merck Serono; Novartis; Boehringer Ingelheim; Genentech; Teva Pharmaceutical Industries Ltd; Pfizer; Baxter Healthcare; GlaxoSmithKline ; Bayer; Gilead Sciences; Janssen; Lundbeck; Sanofi; Esteve; Daiichi Sankyo; Purdue Pharma; AstraZeneca


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.